Search
Policy Forum

Policy Forum Policy Forum articles provide a platform for health policy makers from around the world to discuss the challenges and opportunities in improving health care to their constituencies.

See all article types »

# Regulating the Market in Human Research Participants

• Published: August 01, 2006
• DOI: 10.1371/journal.pmed.0030330
Corrections

31 Oct 2006: Lemmens T, Miller PB (2006) Correction: Regulating the Market in Human Research Participants. PLoS Med 3(10): e447. doi: 10.1371/journal.pmed.0030447 | View correction

### Payments to Health-Care Professionals

Industry research sponsors are increasingly paying finder's fees to health-care professionals to encourage them to recruit patients. Finder's fees can be defined as payments to physicians, nurses, or other health-care professionals for the mere recruitment of research participants. Reports suggest finder's fees ranging between $2,000 and$5,000 per patient are common [15], although it is not always easy to distinguish the reward for the recruitment of patients from remuneration for clinical activities that are part of the research.

These incentives may partly explain the increasing involvement of community-based physicians in clinical research. Between 1988 and 1998, the number of community-based physicians participating in research in the US increased by 60% [16]. Sponsors target community-based physicians because their patient bases are seen as an untapped reserve of potential research participants. Academic researchers, in turn, now feel they must compete with community-based physicians for recruitment incentives, either for personal gain or to pay researchers' salaries.

Direct payments to researchers, often with bonuses for fast recruitment, are not the only tools of the trade. Sponsors may offer other incentives, including authorship priority, paid consulting work, and further research sponsorship [12,17]. For this reason, we use the wider term “recruitment incentive” rather than “finder's fee” to discuss the general ethical and legal issues associated with various practices used to entice physicians into recruiting patients.

### Concerns Raised by Recruitment Incentives

A general concern is that recruitment incentives will encourage physicians to act contrary to their fiduciary obligations to their patients. The prospect of considerable fees for referrals may interfere with the judgment of physicians trusted by patients to act in their best interests. A related concern is potential interference with consent processes. Fraudulent behavior can be dealt with under criminal law [18]. But other forms of influence are likely to be more subtle and therefore harder to control. Researchers who know that enrollment of an additional patient will bring a $20,000 bonus may be tempted to find a way to convince that patient of the “advantages” of participation. #### Patient safety Safety is another important concern: financial interests associated with the recruitment of patients may encourage researchers to disrespect inclusion and exclusion criteria, putting patients at risk. Misconduct at a VA (Veterans Affairs) hospital in Albany, New York, highlights this concern [19,20]. Federal officials launched a criminal investigation against two researchers involved in a cancer study at the hospital in which at least five patients died [21,22]. An inspection report by the US Food and Drug Administration (FDA) concluded that patients' medical records were altered in at least five experimental drug studies, enabling veterans to be enrolled in studies for which they were either too sick or too healthy to qualify [23]. The hospital reportedly received a fee of$5,000 for each patient enrolled [23], and some individual investigators are reported to have received undisclosed recruitment incentives [19]. The junior researcher pled guilty to criminally negligent homicide as well as fraud and was sentenced to six years in prison [24]. The senior researcher was not charged, but the FDA initiated disqualification proceedings against him on September 22, 2004 [25]. As of June 5, 2006, the case was still open (confirmed in a phone call to the FDA's Division of Scientific Investigations on June 5, 2006). Safety concerns may be amplified with the involvement of community-based physicians, who may lack experience in research, who may be overburdened, and who work more in isolation, perhaps making it harder to critically evaluate and discuss research benefits and risks with other professionals.

Patients have become de facto market products.

#### Erosion of public trust in clinical research

More general concerns relate to the public interest in clinical science. In a competitive environment, commercial sponsors enjoy significant control over research. Careful selection of patients and development of research methodology, combined with selective publication, may lead to the approval of minimally effective and potentially harmful drugs. A host of recent controversies indicate how pharmaceutical sponsors have engaged in the selective publication of results, the manipulation of data, the use of ghost authors, and, allegedly, the fraudulent promotion of off-label prescription, on the basis of questionable research [26]. Erosion of scientific integrity risks the health of future patients and places undue burden on publicly funded health care. Further, recruitment incentives are implicated in the distortion of research agendas and priorities [27]. Researchers who conduct publicly funded research may encounter difficulties recruiting patients because they cannot offer significant recruitment incentives. As a result, valuable research may be neglected for research of sometimes questionable scientific importance and clinical value.

### Existing Controls on Recruitment Incentives

Few would argue that patients in trials should be treated as commodities, but patients have become de facto market products, while “market controls” are neither clear nor sufficiently stringent.

Various organizations have taken a stand against certain recruitment practices. The American Medical Association's Council on Ethical and Judicial Affairs stated unequivocally in one opinion that “offering or accepting payment for referring patients to research studies (finder's fees) is unethical” [28]. In a report on finder's fees, the council clarifies the basis for its recommendation, and seems to widen its ambit. It states that “any kind of compensation in return for the referral of patients” is unethical [29]. An earlier general opinion on conflicts of interest indicates, however, that remuneration that is “commensurate with the efforts of the researcher on behalf of the company” is acceptable [30].

The Canadian Medical Association has issued a statement on relations with the pharmaceutical industry that refers to finder's fees [31]. But it fails to clearly prohibit them or to mandate their disclosure, and essentially diverts the issue to institutional review boards (IRBs). Several academic institutions offer more direct guidance, expressly prohibiting finder's fees [32–37]. But since most clinical drug trials now take place outside of academic institutions, such guidance has little impact on the practice. It is also not clear whether academic institutions have thorough control over the research practices in their institutions, even when they have such policies in place.

IRBs are currently neither sufficiently regulated nor independent.

Physicians should, however, be aware that legal and regulatory sanctions may be imposed on them for accepting recruitment incentives. Significant private liability may arise. If physicians purposefully misinform or fail to adequately inform patients of their financial interests, they expose themselves to tort liability for battery or negligence. Moore v. Regents of the University of California [38] suggests that non-disclosure of financial interests by a physician can give rise to a cause of action for breach of fiduciary duty, although a more recent Florida District Court rejected the argument that physicians have to disclose financial interests [39].

Other serious legal consequences, including criminal charges, are also possible [40]. Most US states [41] and some Canadian provinces [42] have statutory frameworks on professional misconduct, with provisions that could apply to research activities. The US federal “anti-kickback statute” also makes it a felony to induce referral of patients covered by federal health-care programs [43]. These statutes generally prohibit the offer or acceptance of rewards for referring patients to health-care providers or facilities. The general terms in which such statutory provisions are constructed suggests that they could readily be applied to sanction the offer or receipt of a broad range of recruitment incentives used in clinical research [40]. The California Business and Professions Code, for example, prohibits the “receipt, or acceptance…of any rebate, refund, commission…or other consideration… as compensation or inducement for referring patients, clients, or customers to any person” [44].

In the US, regulatory authorities have also laid charges under the federal False Claims Act in cases where financial interests were not disclosed to granting agencies, and where researchers violated regulations, compliance with which was a condition for funding [45]. In Canada, significant case law has expanded the potential scope of application of general Criminal Code fraud provisions [46]. Canadian physicians who fail to disclose financial interests in referrals or other forms of advice to patients expose themselves to possible criminal prosecution for fraud, and when the patient's treatment suffers as a result [40].

### Recruitment Incentives and Regulatory Reform

The problems raised by finder's fees cannot be resolved by focusing exclusively on sanctioning the individuals who may accept them. They ought to be addressed as part of a broader institutional and regulatory reform effort designed to address weaknesses in research governance.

Such reforms ought to include specific institutional and regulatory guidance on broad conflict-of-interest issues. Strict but narrow rules on finder's fees may fail to protect participants from the influence of conflicts arising from other arrangements that are harder to detect and control. Several organizations have come up with sensible recommendations to strengthen conflict-of-interest rules. A task force of the Association of American Medical Colleges issued two important reports on investigator [47] and institutional [48] conflicts of interest. The task force strongly recommends that institutions separate the financial management of research from their conduct and oversight, and, further, that they establish independent conflict-of-interest committees. With regard to individuals, it recommends that institutions introduce a rebuttable presumption that individuals holding a significant financial interest in a study may not participate in its conduct.

The DHHS has also recommended the establishment of specialized institutional conflict-of-interest committees in a guidance document: “Financial Relationships and Interests in Research Involving Human Subjects” [49]. If the recommendations of the Association of American Medical Colleges and the DHHS are acted upon, they may go a long way to address concerns about conflicts of interest within academic institutions. However, it is unlikely that the adoption and enforcement of more stringent institutional policies will alone satisfactorily address concerns generated by recruitment incentives.

Regulatory agencies and institutions rely too much on IRBs to evaluate and control conflicts of interest. While the development of specialized conflict-of-interest committees within academic institutions would add a layer of more focused protection, IRBs would presumably still play the central role in protecting research participants from the ill effects of conflicts of interest. Unfortunately, while IRB review can deal with small-scale, specific conflict-of-interest issues, IRBs themselves are currently neither sufficiently regulated nor independent to fulfill their important function.

Various reports clearly indicate that the IRB system is currently facing considerable challenges [50–52]. One of the core problems with regard to IRB review of conflicts of interest is the significant conflicts faced by IRBs themselves. While IRBs have an important public-policy mandate (protection of human research participants), they are deficient with respect to some basic principles of administrative law [53]. Academic IRBs often lack independence or suffer the perception of bias because of the interests of their host institutions in the approval of research. The increasing reliance of academic institutions on private sponsors augments concerns about direct or indirect institutional pressure on IRBs. Many contract research organizations have set up internal IRBs, which suffer from similar conflicts of interest. Further, for most clinical trials involving community-based physicians, commercial IRBs are employed. The legitimacy of the review provided by these IRBs is undermined by an inherent conflict of interest, given that they are paid to make a decision that has an immediate impact on the financial interests of their clients [53,54]. Improvement of the IRB system, for example through the establishment of IRBs with a strong governmentally controlled mandate and exclusive jurisdiction [53], is a logical first step in dealing with problems relating to the increased commercialization of medical research.

There are, however, other solutions that are more radical and simpler. One option is to establish an independent national institute for drug testing, to ensure the reliability of the data supporting drug approval [55,56]. Drug companies seeking to have a drug approved would submit the drug for testing to the institute, which would then negotiate a research protocol with the sponsor. The research would be contracted out to a qualified independent drug-assessment center, which would negotiate contractual terms and matters of data publication with the institute. Other proposals include the establishment of a three-pronged independent drug regulatory authority that would not only control clinical trials and post-marketing studies more directly, but also control drug promotion and publicity [57].

Proposals such as these would do much to safeguard the independence of research. They could also provide a check on competition for research participants. Strict guidelines on recruitment of, and payments to, patients could be established for these drug assessment centers, and clinical trials could be better coordinated. The number of industry-driven exploratory trials—often aimed at coming up with “good data” to support applications and marketing—would also likely decrease. More rigorous review of the merit of trials, and the resulting decrease in their number, could also help alleviate industry concerns. Centralization of patient recruitment and reduction in recruitment competition might make it easier to recruit patients for valuable research, thus also reducing pre-approval time windows. Since these proposals require a thorough overhaul of current drug-regulation structures, and since they will not occur tomorrow, it is important that regulatory and professional agencies immediately investigate other measures, including those recommended above.

### Conclusion

We note one problem raised by our recommendations. They do not address the problem of jurisdiction shopping. Strengthened regulatory structures in North America have resulted in clinical trials being moved even more often to middle- or low-income countries, where recruitment and other research-related costs are cheaper, where regulations either do not exist or may not be adequately enforced, and where research participants are even more vulnerable [58]. These developments are a real cause for concern. Our recommendations for a more stringent regulatory review in the North American context will hopefully inspire others to look at strengthening the national regulatory regimes in other countries and at developing and enforcing international standards for recruitment in clinical trials.

### Acknowledgments

This article draws upon a longer paper by the same authors [40], and on a slightly revised version of this longer paper, published in [59].

### References

1. 1. Pitts G (2003 July 22) Biovail drug campaign causes dilemma in U.S. The Globe and Mail.
2. 2. Abboud L (2005 February 27) Regulators probe marketing incentives at ANS. The Wall Street Journal.
3. 3. Office of Inspector General, United States Department of Health and Human Services (2000) Recruiting human subjects: Pressures in industry-sponsored clinical research. Washington (D. C.): United States Department of Health and Human Services. Available: http://oig.hhs.gov/oei/reports/oei-01-97​-00195.pdf. Accessed 14 June 2006.
4. 4. Ackerman TF (1989) An ethical framework for the practice of paying research subjects. IRB 11: 1–4.
5. 5. Macklin R (1981) On paying money to research subjects: “Due” and “undue” inducements. IRB 3: 1–6.
6. 6. McNeill P (1997) Paying people to participate in research: Why not? Bioethics 11: 390–396.
7. 7. Wilkinson M, Moore A (1997) Inducement in research. Bioethics 11: 373–389.
8. 8. Dickert N, Grady C (1999) What's the price of a research subject? Approaches to payment for participation. N Engl J Med 341: 198–203.
9. 9. Lemmens T, Elliott C (1999) Guinea pigs on the payroll: The ethics of paying research subjects. Account Res 7: 3–20.
10. 10. Larkin M (1999) Clinical trials: What price progress? Lancet 354: 1534.
11. 11. Health Canada Publications (2001) Regulations amending the food and drug regulations (1024–clinical trials). Ottawa: Health Canada Publications. Available: http://www.hc-sc.gc.ca/dhp-mps/compli-co​nform/clini-pract-prat/reg/1024_e.html. Accessed 15 June 2006.
12. 12. Bodenheimer T (2000) Uneasy alliance—Clinician investigators and the pharmaceutical industry. N Engl J Med 342: 1539–1544.
13. 13. Light DW, Lexchin J (2004) Will lower drug prices jeopardize drug research? A policy fact sheet. Am J Bioethics 4: W1–W4.
14. 14. Maresky N (2003) Evaluating your performance metrics and ensuring continuous improvement with effective benchmarking [presentation]. Streamlining and Accelerating Your Clinical Trials. 24–25 March 2003; Toronto, Canada.
15. 15. Goldner JA (2000) Dealing with conflicts of interest in biomedical research: IRB oversight as the next best solution to the abolitionist approach. J Law Med Ethics 28: 379–404.
16. 16. Morin K, Rakatansky H, Riddick FA Jr, Morse LJ, O'Bannon JM 3rd (2002) Managing conflicts of interest in the conduct of clinical trials. JAMA 287: 78–84. et al.
17. 17. Healy D, Cattell D (2003) Interface between authorship, industry and science in the domain of therapeutics. Br J Psychiatry 183: 22–27.
18. 18. Kalb PE, Koehler KG (2002) Legal issues in scientific research. JAMA 287: 85–91.
19. 19. Otto MA (2003 February 6) Researchers under investigation for VA drug study deaths in New York. Medical Research Law & Policy Report. Available: http://www.sskrplaw.com/bioethics/resear​chersinvestigation.pdf. Accessed 15 June 2006.
20. 20. [No authors listed] (2003 February 6) VA medical center probed on clinical trial deaths. Reuters Health eLine. Available: http://sci.rutgers.edu/forum/archive/ind​ex.php/t-2062.html. Accessed 15 June 2006.
21. 21. [No authors listed] (2003 May 28) Federal agents query VA staff. Albany Times Union: A1.
22. 22. Pair R (2003 April 13) U.S. to review research at hospitals for veterans nationwide. The New York Times. 24. Available: http://www.nytimes.com/2003/04/13/nation​al/13VETS.html. Accessed 15 June 2006.
23. 23. Sontag D (2005 February 6) In harm's way: Abuses endangered veterans in cancer drug experiments. The New York Times. 1. Available: http://www.nytimes.com/2005/02/06/nyregi​on/06vets.html?ex=1265432400&en=8fe07dd5​8bf0215a&ei=5088&. Accessed 15 June 2006.
24. 24. Vertanen M (2005 November 21) Ex-VA researcher sentenced in drug scandal. WJLA News. Available: http://www.wjla.com/news/stories/1105/27​9747.html. Accessed 15 June 2006.
25. 25. U.S. Food and Drug Administration (2004) Notice of initiation of disqualification proceeding and opportunity to explain (NIDPOE). Available: http://www.fda.gov/foi/nidpoe/n32l.htm. Accessed 22 June 2006.
26. 26. Lemmens T (2005) Leopards in the temple: Restoring scientific integrity to the commercialized research scene. J Law Med 32: 641–657.
27. 27. Baird P (2003) Getting it right: Industry sponsorship and medical research. CMAJ 168: 1267–1269.
28. 28. Council on Ethical and Judicial Affairs, American Medical Association (2000) Fee splitting: Referrals to health care facilities (Opinion E-6.03). Chicago: American Medical Association. Available: http://www.ama-assn.org/ama/pub/category​/8366.html. Accessed 15 June 2006.
29. 29. Council on Ethical and Judicial Affairs, American Medical Association (1994) Finder's fees: Payment for the referral of patients to clinical research. Chicago: American Medical Association.
30. 30. Council on Ethical and Judicial Affairs, American Medical AssociationChicago: American Medical Association. Available: http://www.ama-assn.org/ama/pub/category​/8470.html. Accessed 15 June 2006.
31. 31. Canadian Medical Association (2001) Physicians and the pharmaceutical industry. Ottawa: Canadian Medical Association. Available: http://policybase.cma.ca/policypdf/PD01-​10.pdf. Accessed 15 June 2006.
32. 32. University of Toronto Faculty of Medicine (2003) Policy on the offer and acceptance of finders fees or completion fees in research involving human subjects. Available: http://www.facmed.utoronto.ca/scripts/in​dex_.asp?action=31&U_ID=0&N_ID=13&P_ID=9​976. Accessed 22 June 2006.
33. 33. University of Washington (2002) Policy prohibiting the use of enrollment incentives in human subjects research. Available: http://www.washington.edu/research/osp/e​nrollment.html. Accessed 15 June 2006.
34. 34. University of Rochester Office of Research and Project Administration (2002) University of Rochester policy on enrollment incentive payments by or to university clinical trial researchers. Available: http://www.rochester.edu/ORPA/policies/i​ncenpay.pdf. Accessed 15 June 2006.
35. 35. University of Tennessee (1991) Finder's fees. Available: http://www.utmem.edu/policies/w932_docum​ent_show.php?p=237. Accessed 15 June 2006.
36. 36. Wayne State University (2001) Finder's fee policy. Available: http://www.hic.wayne.edu/hicpol/finders.​htm. Accessed 15 June 2006.
37. 37. McCrary SV, Anderson CB, Jakovljevic J, Khan T, McCullough LB (2000) A national survey of policies on disclosure of conflicts of interest in biomedical research. N Engl J Med 343: 1621–1626.
38. 38. Moore v. Regents of the University of California 793 2.Pd 479 (Cal. 1990).
39. 39. United States District Court, S.D. Florida, Miami Division (2003) Greenberg v. Miami Children's Hospital Research Institute. Wests Fed Suppl 264: 1064–1078.
40. 40. Lemmens T, Miller PB (2003) The human subjects trade: Ethical and legal issues surrounding recruitment incentives. J Law Med Ethics 31: 398–418.
41. 41. Fabrikant R, Kalb PE, Hopson MD, Bucy PH (2002) Health care fraud: Enforcement and compliance. New York: Law Journal Press. p.
42. 42. Choudhry S, Choudhry NK, Brown AD (2004) Unregulated private markets for health care in Canada? Rules of professional misconduct, kickbacks to physicians and physician self-referral in Canada. CMAJ 170: 1115–1118.
43. 43. U.S. House of Representatives (2001) Anti-Kickback Statute. 42 United States Code: 1320a–1327b. Available: http://frwebgate.access.gpo.gov/cgi-bin/​getdoc.cgi?dbname=browse_usc&docid=Cite:​+42USC1320a-7b. Accessed 15 June 2006.
44. 44. California Business and Professions Code Section 650. Available: http://www.leginfo.ca.gov/cgi-bin/displa​ycode?section=bpc&group=00001-01000&file​=650-657. Accessed 22 June 2006.
45. 45. Kalb PE, Koehler KG (2002) Legal issues in scientific research. JAMA 287: 85–91.
46. 46. Davis K, Roy J (1998) Fraud in the Canadian courts: An unwarranted expansion of the scope of the criminal sanction. CBLJ 30: 210–238.
47. 47. AAMC Task Force on Financial Conflicts of Interest in Clinical Research (2003) Protecting subjects, preserving trust, promoting progress I: Policy and guidelines for the oversight of individual financial interests in human subjects research. Acad Med 78: 225–236.
48. 48. AAMC Task Force on Financial Conflicts of Interest in Clinical Research (2003) Protecting subjects, preserving trust, promoting progress II: Principles and recommendations for oversight of an institution's financial interests in human subjects research. Acad Med 78: 237–245.
49. 49. United States Department of Health and Human Services (2004) Financial relationships and interests in research involving human subjects: Guidance for human subject protection. Washington (D. C.): United States Department of Health and Human Services. Available: http://www.hhs.gov/ohrp/humansubjects/fi​nreltn/fguid.pdf. Accessed 15 June 2006.
50. 50. United States Department of Health and Human Services, Office of Inspector General (1998) Institutional review boards: A time for reform. Washington (D. C.): United States Department of Health and Human Services. Available: http://oig.hhs.gov/oei/reports/oei-01-97​-00193.pdf. Accessed 15 June 2006.
51. 51. National Bioethics Advisory Commission (2001) Ethical and policy issues in research involving human participants. Bethesda (Maryland): National Bioethics Advisory Commission. Available: http://www.georgetown.edu/research/nrcbl​/nbac/human/overvol1.pdf. Accessed 15 June 2006.
52. 52. Institute of Medicine (2002) Integrity in scientific research: Creating an environment that promotes responsible conduct. Washington (D. C.): National Academies Press.
53. 53. Lemmens T, Freedman B (2000) Ethics review for sale? Conflict of interest and commercial research review boards. Milbank Q 78: 547–584.
54. 54. Lemmens T, Thompson A (2001) Non-institutional commercial review boards in North America: A critical appraisal and comparison with IRBs. IRB 23: 1–12. Available: http://www.law.utoronto.ca/documents/Lem​mens/noninstitutionalboards.pdf. Accessed 16 June 2006.
55. 55. Krimsky S (2003) Science in the private interest: Has the lure of profits corrupted biomedical research? Lanhan (Maryland): Rowman & Littlefield Publishers. p.
56. 56. Angell M (2004) The truth about the drug companies: How they deceive us and what to do about it. New York: Random House. p.
57. 57. Ray WA, Stein CM (2006) Reform of drug regulation—Beyond an independent drug-safety board. NEJM 354: 194–201.
58. 58. Petryna A (2005) Ethical variability: Drug development and globalizing clinical trials. Amer Ethnol 32: 183–197.
59. 59. Lemmens T, Waring DR (2006) Law and ethics in biomedical research: Regulation, conflict of interest, and liability. Toronto: University of Toronto Press. pp. 132–179. pp.

Ambra 2.10.5 Managed Colocation provided
by Internet Systems Consortium.